Skip to main content
SpringerLink
Log in

Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy

  • Original Article
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objectives

The intention of this study is to describe the impact and underlying potential basis of the prostate-specific antigen (PSA) flare-up phenomenon in patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel-based chemotherapy.

Methods

We retrospectively identified 74 consecutive patients who received docetaxel/estramustine-based chemotherapy at our institution. Patients were evaluated based on modified criteria from the Prostate-Specific Antigen Working Group regarding survival and toxicity. Additionally, two androgen receptor mutations derived from patients with advanced disease were analyzed for promiscuous transactivation activity.

Results

The 74 patients were stratified into four groups: response, partial response, flare-up-initial PSA elevation, and progression. Median survival in the flare-up group (n = 8) was 20 months and did not differ from the response group (p = 0.564). The flare-up group showed a maximum PSA elevation from baseline between 3.4 and 28.3% (between three and six weeks) followed by PSA decline ≥50% from the baseline level in seven of the eight patients. The androgen receptor mutations AR877 and AR715 displayed a 37.5- and 5.2-fold increase in transactivation activity by progesterone and a 12.6- and 5.4-fold increase by estrogen compared to the ARWT, respectively.

Conclusions

A considerable portion of HRPC patients experience an initial PSA flare-up under systemic chemotherapy. In this study, occurence of flare-up phenomenon did not impact survival. Chemotherapy should be continued a minimum of six weeks before removing patients from a docetaxel-based regimen. We showed evidence that co-medication with dexamethasone/prednisolone and/or estramustine itself can induce an initial PSA flare-up via androgen receptor mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

    Article  PubMed  Google Scholar 

  2. Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424

    Article  PubMed  CAS  Google Scholar 

  3. Eisenberger MA, Blumenstein BA, Crawford ED et al (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036–1042

    Article  PubMed  CAS  Google Scholar 

  4. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29

    PubMed  Google Scholar 

  5. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098–1109

    Article  PubMed  CAS  Google Scholar 

  6. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  7. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  8. Oudard S, Banu E, Beuzeboc P et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343–3351

    Article  PubMed  CAS  Google Scholar 

  9. Noguchi K, Uemura H, Harada M et al (2001) Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist. Int J Clin Oncol 6:29–33

    Article  PubMed  CAS  Google Scholar 

  10. Fossa SD, Vaage S, Letocha H et al (2002) Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)–delayed response and flare phenomenon should be considered. Scand J Urol Nephrol 36:34–39

    PubMed  CAS  Google Scholar 

  11. Heidenreich A, Sommer F, Ohlmann CH et al (2004) Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 101:948–956

    Article  PubMed  CAS  Google Scholar 

  12. Olbert PJ, Hegele A, Kraeuter P et al (2006) Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 17:993–996

    Article  PubMed  CAS  Google Scholar 

  13. Bubley GJ, Carducci M, Dahut W et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461–3467

    PubMed  CAS  Google Scholar 

  14. Kreis W, Budman DR, Fetten J et al (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33–38

    Article  PubMed  CAS  Google Scholar 

  15. Hudes GR, Nathan F, Khater C et al (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156–3163

    PubMed  CAS  Google Scholar 

  16. Pienta KJ, Redman B, Hussain M et al (1994) Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005–2012

    PubMed  CAS  Google Scholar 

  17. Nelius T, Reiher F, Lindenmeir T et al (2005) Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie 28:573–578

    Article  PubMed  CAS  Google Scholar 

  18. Kelly WK, Scher HI, Mazumdar M et al (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607–615

    PubMed  CAS  Google Scholar 

  19. Sridhara R, Eisenberger MA, Sinibaldi VJ et al (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944–2953

    PubMed  CAS  Google Scholar 

  20. Petrylak DP, Scher HI, Li Z et al (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70:2870–2878

    Article  PubMed  CAS  Google Scholar 

  21. Roessner M, de Wit R, Tannock IF, Yateman N, Yao S-L, Yver A, Eisenberger MA, on behalf of the TAX 327 Investigators (2005) Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. J Clin Oncol 23:391: abstract 4554

    Google Scholar 

  22. Liu AY, True LD, LaTray L et al (1999) Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 40:192–199

    Article  PubMed  Google Scholar 

  23. van der Poel HG, Oosterhof GO, Schaafsma HE et al (1997) Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology 49:652–657

    Article  PubMed  Google Scholar 

  24. Taplin ME, Rajeshkumar B, Halabi S et al (2003) Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. J Clin Oncol 21:2673–2678

    Article  PubMed  CAS  Google Scholar 

  25. Brinkmann AO, Trapman J (2000) Prostate cancer schemes for androgen escape. Nat Med 6:628–629

    Article  PubMed  CAS  Google Scholar 

  26. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45

    Article  PubMed  CAS  Google Scholar 

  27. Yeh S, Hu YC, Rahman M et al (2000) Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Nat Acad Sci U S A 97:11256–11261

    Article  PubMed  CAS  Google Scholar 

  28. Heinlein CA, Chang C (2002) Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175–200

    Article  PubMed  CAS  Google Scholar 

  29. Godoy-Tundidor S, Hobisch A, Pfeil K et al (2002) Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 8:2356–2361

    PubMed  CAS  Google Scholar 

  30. Lu ML, Schneider MC, Zheng Y et al (2001) Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 276:13442–13451

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Texas Tech University Health Sciences Center, Medical Office Plaza, Suite 260, 3502 9th Street, Lubbock, TX, 79415, USA

    Thomas Nelius, Werner de Riese & Stephanie Filleur

  2. Department of Urology, Otto-von-Guericke-University Magdeburg, 39120, Magdeburg, Germany

    Thomas Nelius & Tobias Klatte

  3. Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Tobias Klatte

Authors
  1. Thomas Nelius
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tobias Klatte
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Werner de Riese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephanie Filleur
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Nelius.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelius, T., Klatte, T., de Riese, W. et al. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int Urol Nephrol 40, 97–104 (2008). https://doi.org/10.1007/s11255-007-9221-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-007-9221-y

Keywords

Search

Navigation